Group 1 - The company has adjusted the maximum repurchase price from 12 RMB per share to 17 RMB per share and extended the implementation period by 6 months, now ending on February 27, 2026 [16][21][36] - The repurchase plan aims to use self-owned funds and may include special loans for stock repurchase [19][20] - As of the disclosure date, the company has repurchased 1,482,364 shares, accounting for 0.731% of the total share capital, with a total expenditure of approximately 14.29 million RMB [20][21] Group 2 - The company raised a total of 845.17 million RMB from the public offering, with a net amount of 750.86 million RMB after deducting various fees [2][4] - The company has established a management system for the raised funds, ensuring they are stored in dedicated accounts and used according to regulatory requirements [4][5] - The company has not encountered any abnormal situations regarding the investment projects funded by the raised capital [7][8]

Core Viewpoint - Zhejiang Haizheng Biomaterials Co., Ltd. has announced an adjustment to its share repurchase plan, increasing the maximum repurchase price from 12 RMB per share to 17 RMB per share and extending the implementation period by 6 months until February 27, 2026 [1][3]. Summary by Sections 1. Basic Information on Share Repurchase - The company plans to repurchase its issued A-shares using its own funds through the Shanghai Stock Exchange, initially set at a maximum price of 12 RMB per share and a total repurchase fund between 20 million RMB and 30 million RMB [1][2]. 2. Progress of Share Repurchase - As of the disclosure date, the company has repurchased a total of 1,482,364 shares, accounting for approximately 0.73% of the total share capital of 202,678,068 shares, with a total expenditure of approximately 14.29 million RMB [3]. 3. Reasons for Adjusting the Repurchase Plan - The adjustment to the repurchase price and extension of the implementation period are due to the recent increase in the company's stock price, which exceeded the previously set maximum repurchase price. This change aims to ensure the smooth execution of the repurchase plan and protect shareholder interests [3][4]. 4. Rationality and Necessity of the Adjustment - The adjustment complies with relevant regulations and is based on market conditions and the progress of the repurchase. The new maximum price is set at 150% of the average trading price over the last 30 trading days prior to the board's decision [3][4]. 5. Decision-Making Process for the Adjustment - The adjustment was approved by the company's seventh board of directors' seventeenth meeting, with all directors present. This matter does not require submission to the shareholders' meeting for approval [5].

Core Viewpoint - The article discusses the transformative potential of adhesive hydrogels in biomedical applications, emphasizing their inherent tissue adhesion properties and the need for controllable degradation rates to enhance their effectiveness [2][10]. Group 1: Advantages of Adhesive Hydrogels - Adhesive hydrogels possess intrinsic tissue adhesion, eliminating the need for additional fixation, making them promising alternatives to traditional sutures and staples [2]. - They are ideal carriers for delivering functional additives such as cells and drugs, enhancing stability and performance compared to conventional hydrogels [2]. - These hydrogels can be utilized in the production of functional wound dressings to promote tissue regeneration and can also repair other medical devices, reducing secondary tissue damage caused by traditional fixation methods [2]. Group 2: Research Findings - A study published by Professor Bu Yazhong's team at Xi'an Jiaotong University revealed a method to control the degradation of adhesive hydrogels by incorporating succinamide esters [3][8]. - The research demonstrated that by adjusting the degradation rate, therapeutic effects varied across different preclinical scenarios, providing practical guidelines for designing biodegradable materials for specific applications [3][10]. - The study established a correlation between in vitro and in vivo degradation patterns, showing that the optimal degradation rate of adhesive hydrogels depends on their intended use, such as rapid degradation for abdominal adhesion prevention and slow degradation for cardiac surgery [6][8]. Group 3: Implications for Future Research - The controllable degradation method developed in this research can be extended to other biomaterials, potentially broadening the applications of adhesive hydrogels in various medical fields [8][10]. - The findings suggest that the degradation speed can be tailored to match the tissue regeneration needs, exemplified by the use of cryogels for liver injury repair, which first stops bleeding and then promotes liver regeneration [6].

Group 1 - The company, Zhejiang Hisun Biomaterials Co., Ltd., will hold a half-year performance briefing on August 21, 2025, from 15:00 to 16:00 [1][2] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [1][2] - Key company personnel, including the Chairman and General Manager, will participate in the briefing, with potential adjustments to attendees based on special circumstances [2] Group 2 - Investors can participate in the briefing by logging into the Shanghai Stock Exchange Roadshow Center on the scheduled date and time [2] - Questions from investors can be submitted from August 14 to August 20, 2025, through the Roadshow Center or via the company's email [1][2] - After the briefing, investors can access the main content and details of the event through the Roadshow Center [3]

Core Viewpoint - The announcement details the upcoming listing and circulation of 6,390,100 restricted shares of Zhejiang Haizheng Biomaterials Co., Ltd., which will be available for trading on August 18, 2025, following the expiration of the lock-up period for certain shareholders [1][2]. Summary by Sections Listing Details - The total number of shares to be listed is 6,390,100, representing 3.15% of the company's total share capital [2]. - The shares will be available for trading starting on August 18, 2025, due to the preceding non-trading day on August 16, 2025 [1]. Shareholder Information - The restricted shares are held by three entities: Taizhou Jiaojiang Chuanghe Enterprise Management Partnership (Limited Partnership), Taizhou Jiaojiang Chuangyou Enterprise Management Partnership (Limited Partnership), and Taizhou Chuangyi Enterprise Management Service Center (Limited Partnership) [2]. - The lock-up period for these shareholders was set for 36 months from the date of the company's initial public offering [2]. Changes in Share Capital - Since the formation of these restricted shares, there have been no changes in the company's share capital due to profit distribution or capital increase [2]. Commitments from Shareholders - The shareholders have committed not to transfer or manage their shares during the lock-up period and to comply with relevant regulations when reducing their holdings [3][4]. - Any income obtained from violations of these commitments must be returned to the company [3]. Management Commitments - Senior management and core technical personnel have similar commitments regarding their shares, including restrictions on transfers during the lock-up period and specific conditions post-lock-up [5][7]. - If the company's stock price falls below the initial offering price for a specified period, the lock-up period may be automatically extended [9]. Regulatory Compliance - The underwriting institution, CITIC Securities Co., Ltd., has confirmed that the listing of these restricted shares complies with relevant laws and regulations [10][11].

Core Viewpoint - The report outlines the verification opinion of CITIC Construction Investment Securities Co., Ltd. regarding the listing and circulation of restricted shares from the initial public offering (IPO) of Zhejiang Haizheng Biological Materials Co., Ltd. on the Sci-Tech Innovation Board, confirming compliance with relevant regulations and the accuracy of information disclosure [1][8]. Summary by Sections Type of Restricted Shares - The restricted shares being listed are part of the company's IPO, totaling 50,669,517 shares, which were listed on August 16, 2022. The total share capital after the IPO is 202,678,068 shares, with restricted shares accounting for 156,470,896 shares (77.20%) and unrestricted shares for 46,207,172 shares (22.80%) [1]. Shareholder Information - The restricted shares involve three shareholders: Taizhou Jiaojiang Chuanghe Enterprise Management Partnership (Limited Partnership), Taizhou Jiaojiang Chuangyou Enterprise Management Partnership (Limited Partnership), and Taizhou Chuangyi Enterprise Management Service Center (Limited Partnership), holding a total of 6,390,100 shares, representing 3.15% of the current total share capital. The lock-up period for these shares is 36 months from the listing date, expiring on August 16, 2025, with the actual listing date adjusted to August 18, 2025, due to a non-trading day [2][3]. Changes in Share Capital - Since the formation of the restricted shares, there have been no changes in the company's share capital due to profit distribution or capital increase [2]. Commitments by Shareholders - The shareholders have committed not to transfer or manage their shares for 36 months post-listing and to comply with relevant regulations during any future share reductions. Any income from violations will be returned to the company [3][4]. Lock-up Period Extension - The lock-up period for certain shareholders was automatically extended by six months to February 15, 2026, due to the stock price falling below the IPO price for 20 consecutive trading days [5][7]. Total Restricted Shares for Listing - The total number of restricted shares for listing is 6,390,100 shares, with the listing date set for August 18, 2025 [7]. Verification Opinion - The sponsor institution confirms that the listing of the restricted shares complies with the Company Law, Securities Law, and relevant regulations, and that the information disclosure is true, accurate, and complete [8].

Core Viewpoint - The controlling shareholder of Hyaluronic Acid leader Huaxi Biological (688363) plans to increase its stake in the company by investing between 200 million to 300 million yuan, with a maximum purchase price of 70 yuan per share [2][8]. Group 1: Shareholder Actions - Huaxi Xingyu Investment Co., Ltd. intends to increase its shareholding in Huaxi Biological, reflecting confidence in the company's long-term value and its ability to lead industry advancements through foundational research [4][8]. - As of August 7, Huaxi Xingyu directly holds 58.86% of Huaxi Biological, with associated parties holding minor stakes [8]. Group 2: Company Performance and Strategy - Huaxi Biological recently celebrated its 25th anniversary and has experienced both significant growth and challenges over the years [11]. - The company reported its highest performance in 2022, with a net profit of 971 million yuan, while profits for 2023, 2024, and the first quarter of 2025 were 593 million yuan, 174 million yuan, and 102 million yuan, respectively [11]. - The company aims to integrate scientific innovation with market transformation, positioning itself as a leader in the Chinese biomanufacturing industry [11][12]. Group 3: Research Focus - Huaxi Biological's research has shifted towards glycomics and cell biology, with applications in aging intervention and regenerative medicine [12]. - The company believes that the solid foundation of scientific research will prevail after market fluctuations [12].

Group 1 - The Xinjiang Uygur Autonomous Region's Uusu City Market Supervision Bureau is actively engaging with local companies to support innovation and development [1][2] - The bureau is focusing on understanding the technological innovations and intellectual property achievements of companies like the Mianfu Yuan Flour Processing Plant and providing comprehensive services in key technology breakthroughs, patent layout, and brand building [1] - The bureau emphasizes personalized guidance for companies, particularly in intellectual property strategy planning and high-value patent cultivation, as part of its "One Enterprise, One Policy" approach [1] Group 2 - The bureau is enhancing risk management and safety controls at companies such as Kaisa (Uusu) Biomaterials Co., Ltd., focusing on the safety of special equipment and food management in employee cafeterias [2] - A comprehensive management system is being established to strengthen production process control and ensure safety from the source to the end [2] - The bureau aims to improve market supervision mechanisms through detailed management across all processes and dimensions, reinforcing safety measures for special equipment and food [2]

百赛飞是生物材料表面改性技术领域的国家专精特新"小巨人"企业，自2017年成立以来，历经多轮融资 及扩建，率先创建了功能涂层全产业链的技术服务平台，涵盖自主研发的多系列医用涂层产品、自动化 涂覆装备/产线、涂层AI质检及分析仪器，是国内拥有医用涂层相关专利最多的企业。 该公司同时主导建立了国内首个介入医械涂层牢固度相关行业标准，并有多项填补国内空白的抗凝血、 抗菌等医用涂层相关团体标准发布；建成国内极少数符合危化品与医用品双重规范标准的医用涂层规模 化生产基地，百赛飞涂层取得NMPA、FDA或CE医疗器械注册证，数百家医疗器械厂家产品已应用。 本轮融资有望进一步推动百赛飞全面加速技术创新和市场全球化进程。该公司将通过加码先进表面改性 技术，打造国际领先的高性能涂层平台；依托一站式功能涂层全套解决方案，推进下游带特殊功能涂层 创新器械的规模化生产与上市，实现产业链补链与自主可控；结合自动化装备制造基础与AI技术，扩 建国际化ODM工厂，形成全球化服务能力；并基于大语言模型的智能化运维管理体系，提升运营与服 务效率。 百赛飞创始人陈红称，新一轮融资的完成又是一个新的起点。我们将以"技术+产能+智能"的三重跃 迁， ...

Group 1 - The company announced a share repurchase plan with a total expected amount between 20 million to 30 million RMB [1] - The repurchase period is set from August 28, 2024, to August 27, 2025 [1] - The repurchased shares will be used for employee stock ownership plans or equity incentives [1] Group 2 - As of the latest update, the company has repurchased a total of 1,482,364 shares, representing 0.731% of the total share capital [1] - The total amount spent on repurchased shares is 14,288,602.36 RMB, with a price range of 7.76 RMB to 10.53 RMB per share [1][2] - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations [2]